JGM is likely to be affected. As novel genes and variants associated with MCD are discovered using next-generation sequencing (NGS) technology, an updated classification system for MCD has become more reliant on NGS findings [1, 4] . Identification of disease-causing mutations, including inherited or de novo mutation, in MCD has revealed the molecular genetic basis of clinical manifestations [5] [6] [7] [8] [9] . As an example, recently identified genes responsible for microcephaly were found to encode DNA repair systems and centrosomal proteins that are crucial for regulating cell division [5, 10, 11] .
Introduction
Malformations of cortical development (MCD) include various structural abnormalities of the cerebral cortex that arise during formation of the cortical plate [1] . Development of the cerebral cortex is complex and involves proliferation, migration, and organization of neural progenitor cells [2, 3] . Abnormalities at any stage during cerebral cortex development could result in a wide range of phenotypes, ranging from focal cortical dysplasia to hemimegalencephaly (HME) which show the enlargement of one hemisphere of brain (Fig. 1 ). Traditional classification of MCD has mainly been based on which developmental process Although the identification of disease-associated mutations allows us to elucidate the molecular mechanisms of MCD, our understanding of the biological and pathological functions of the identified mutations is unclear. This has resulted in difficulties directly linking these disease-associated mutations to MCD. Genetic studies without disease modeling are not sufficient for revealing the causal relationship between genes and disease phenotypes. Disease modeling in combination with genetic studies and functional analyses at the organism level are required for elucidating causal relationships [12] . In this review, we describe the identification of novel genes associated with MCD using NGS, and discuss how these identified genes can be functionally validated by in vivo disease modeling.
NGS-based Identification of Novel Genes
The advent of NGS technologies has significantly altered and accelerated research into the human genome. Among the various types of NGS platforms, whole-genome sequencing (WGS) can detect most genetic variations, such as single nucleotide variants, insertions/deletions, and copy number variation and rearrangement [13] . While the entire genome is A B FCD HME sequenced in WGS, whole-exome sequencing (WES) enriches the ~1% of genomic DNA that encodes proteins. Because of issues associated with data volume and cost effectiveness, WES is the more popular sequencing platform for identifying diseasecausing mutations [12] . In the WES platform, the coding regions of entire genome are captured from sheared genomic DNA fragments, using labeled hybridization probes that bind to the protein-coding sequences [14] . The raw sequencing data from WES can be processed using well-established pipelines, such as Best Practices stipulated by the Broad Institute, that encompass pre-processing, variant discovery, and evaluation of variants [15, 16] (Fig. 2) . A fundamental limitation of WES is that it is unable to assess non-coding regions; however, many diseasecausing genes involved in cortical developmental disorders have been identified using this technology [12, 17] . In the following paragraph, we discuss specific approaches for detecting diseasecausing mutations, including inherited and de novo somatic mutations.
Detection of inherited mutations
Prior to the development of NGS technologies, linkage analysis was mainly used to identify inherited mutations. Linkage analysis requires a large number of affected and unaffected individuals, spanning multiple generations [17] . The recent advent of NGS has altered how we identify inherited mutations in Mendelian disorders. NGS-based procedures require a smaller number of families than for linkage analysis. In addition, the raw sequencing data generated during NGS can be easily and rapidly processed using established protocols. As these tools for identifying mutations have developed, experimental design has become more important than sequencing itself with respect to studying inherited mutations.
To identify the mode of inheritance for mutations (autosomal recessive, autosomal dominant, or sex chromosome linked mutation), describing the family structure represented by pedigrees is essential. Family pedigree influences the number and selection of individuals to be sequenced, along with the data analysis methods employed. NGS-based identification of heterozygous, and homozygous mutations in autosomal recessive disorders is relatively straightforward. Homozygous variants in affected siblings and heterozygous variants in unaffected parents can be predicted; therefore, searching for overlapping mutations between siblings and parents (carrier) could determine disease-associated mutations. Using this strategy, several disease-causing genes have been identified in MCD [5] [6] [7] 11, 18, 19] . A recent study regarding occipital cortical gyration abnormalities, which is characterized by the presence of pachygyria and polymicrogyria, identified autosomal recessive LAMC3 mutations [18] . In consanguineous families, the same heterozygous mutation found in both parents is commonly inherited in affected individuals. However, in a family without consanguinity, compound heterozygous mutations should be considered [12] . A recent analysis of nonconsanguineous families with polymicrogyria, exhibiting shallow sulci and abnormal lamination, revealed a compound heterozygous mutation in the WDR62 gene. This gene is a wellknown disease-causing gene for a wide spectrum of cerebral cortical malformations, including microcephaly, lissencephaly, and pachygyria [19] .
NGS-based detection of disease-causing genes in autosomal dominant diseases has been more challenging. For these diseases, it is not possible to rely on the homozygosity of an allele to detect disease-causing genes. Thus, it should be more careful to select one or a few disease-associated variants from a large number of candidate heterozygote variants [17] . The analysis of this type of mutations may stay on the present state for a while.
Detection of de novo somatic mutations
There is an increasing amount of evidence to support the importance of de novo mutations in neurodevelopmental diseases other than cancer [8, 9, 20, 21] . During mitosis, de novo somatic mutations can occur without affecting cellular proliferation. Somatic mutations can occur at any stage during development with the frequency of mutated alleles varying. This is dependent on the timing of the mutation, which is consistent with mosaicism [22] . Because somatic mosaic mutations only exist in affected tissues, a simple comparison of non-overlapping mutations between affected and unaffected tissues is able to detect disease-associated mutations. Using this strategy, researchers have elucidated basic pathways related to cortical malformation [8, 9, 20, 21] . A recent study of HME led to the identification of brain-specific somatic activating mutations in the AKT3 (V-akt murine thymoma viral oncogene homolog 3) gene, which encodes serine-threonine kinase. AKT3 is located upstream from the gene MTOR (mechanistic target of rapamycin), which is highly expressed in the developing brain during corticogenesis [20] . In addition, HME can also be caused by somatic mutations in other genes of the same pathway, including PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) and MTOR [8] . These studies suggest that brain overgrowth can result from mutations in specific pathways that are responsible for the regulation of growth.
NGS analysis for somatic mutations consists of three steps: pre-processing; variant discovery; and variant evaluation (Fig.  2) . Although there exists a general consensus regarding preprocessing protocols for preparing analysis-ready files from raw data, the numerous variant discovery protocols in use remain controversial. Therefore, various types of mutation callers are used depending on the type of mutation [23] . Each algorithm is based on different probability models; the variants reproducibly called by a number of independent algorithms are likely to be true variants rather than those called using a single algorithm. Therefore, the use of multiple detectors is required for improving the accuracy of somatic mutation detection [24] . In a recent study, it was shown that a consensus approach using multiple detectors provided high-confidence putative variants, by removing false positive predictions in each algorithm [25] . However, the further research into the optimum combinations of algorithms is required.
Although a multiple detector strategy is able to call true variants, many of the called variants are non-pathogenic. To select variants for functional studies among those that are called, prioritization of variants is essential. Various scoring system, such as polyphen, scale-invariant feature transform and mutation assessor can be used to prioritize causal variants to increase filtering efficiency [26] [27] [28] . However, each annotation method contains parameters that make it difficult to estimate the relative importance of an independent annotation. To resolve these limitations, a general framework for integrating these various scores into a single value was recently introduced [29] . Despite these efforts, the prioritization of variants cannot fully resolve their biological functions in the context of diseases.
Functional Validation of Identified Variants
The major goal of genetic studies is to reveal the underlying pathogenesis of a disease and gain insights into the biological relevance of the relationship between genes and disease phenotypes. Although in vitro studies can help elucidate the molecular functions of identified variants, the in vitro environment does not necessarily recapitulate the physiological environment of an organism. To understand the biological function of identified variants in an organism, animal models carrying the disease-causing mutations are required.
Knockout and knock-in mouse models
Historically, mice have been widely used in laboratories as animal models. The rapid development of genetic engineering techniques since the 1980s has facilitated greater use of knockout (KO) and knock-in (KI) mice [30] . In KO mice, one or more target genes have been inactivated, while in KI mice disease-associated variant genes have been introduced into the mouse genome. Variants that confer a gain of function, or a loss of function, often result in alterations of the mouse phenotype including the appearance, behavior and molecular characteristics. As an example, in the tuberous sclerosis (TSC) KO mouse, the Tsc1 or Tsc2 genes are inactivated and mice exhibit many of the pathological characteristics of TSC, such as cytomegalic neuron, heterotopic neuron and astrocytosis [31, 32] . In this particular model, the key neurological symptoms of TSC, such as intellectual disability and epilepsy, can be easily observed.
Another important genetic engineering technique, which was established in 1994, is the site-specific Cre-LoxP recombination system [33] . In this system, a specific target gene flanked by Brains were removed at embryonic day 18 (E18) and fixed; then, they were examined using a fluorescence stereomicroscope.
In utero electroporation(E14) GFP expression(E18)
LoxP sequences is inactivated in a single organ or cell type, rather than the entire organism, through the region-or timespecific expression of Cre recombinase. This technique has helped elucidate cell-type or tissue-specific effects of diseasecausing genes or mutations. Using Cre-LoxP recombination, a mouse overexpressing LIS1 in the brain was generated; these mice had smaller brains, migration deficits, and exhibited loss of cellular polarity similar to that seen in lissencephaly patients [34] . However, there are some limitations to Cre-LoxP recombination, such as the maintenance of multiple lines, flanking gene effects, and embryonic lethality [35] [36] [37] . In addition, the lack of a specific promoter to control the expression of genes at a specific point in time, or in a particular region, limits the application of the mouse generated by Cre-loxP system [38] . Thus, the necessity of more efficient tools to control the gene expression arises in the research field of cortical development.
Brain somatic mutation mouse modeling
In recent years, in utero electroporation has emerged as an effective tool for manipulating gene expression in the brain at specific time points, and among particular cell populations [39] (Fig. 3) . A target gene can be delivered to neural precursor cells, located in the ventricular zone, by injecting plasmid DNA into the mouse ventricle. Various sub-populations of neural progenitor cells can be transfected, depending on the stage of the embryo, or the location of where the electrical pulse is administered [40] . This technique is particularly useful for investigating basic mechanisms of cortical development, including migration and regional patterning [41, 42] . Combining this technique with either RNA interference or Cre-LoxP recombination methods allows for both gain of function, and loss of function to be induced [43] . One of the most useful features of in utero electroporation is that it allows for focal cortical malformations to be recapitulated. Although TSC1 conditional KO mice can be generated by crossing with Cre lines, they only mimic some of the features of TSC seen in patients such as seizure and dysmorphic neuron and do not show the heterotopic lesions containing the abnormal cells. In a recent study, discrete TSC-like mice were generated by in utero electroporation and were found to have heterotopic nodules characteristic of TSC [44] . Imprecise spatial control of gene expression, due to manually directing the electrode, is the most challenging problem of in utero electroporation. More accurate spatial control could be possible if plasmids carrying a specific promoter sequence were selectively expressed in target brain areas [45] .
Conclusion
In the era of NGS, molecular genetic studies are rapidly shifting toward a more translational focus, with an attempt to bridge the gap between basic science and understanding the pathology of human diseases. Elucidating the genetic basis of MCD and generating appropriate mouse models have improved our understanding of the underlying mechanisms of these disorders and provided the opportunity to develop effective therapies [46] . The next subject in cortical development research will be to translate the large volume of genetic data for clinical applications.
